Margarita Vlachou
National and Kapodistrian University of Athens
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Margarita Vlachou.
Letters in Drug Design & Discovery | 2005
Andrew Tsotinis; Margarita Vlachou; Spyridon Zouroudis; A. Jeney; Ferenc Timár; David E. Thurston; Christos Roussakis
An expeditious four-step synthesis of the 1H-pyrrolo[2,3-f]quinoline-2- carboxamides (5a-h) is described. Readily available 6-quinolinecarboxaldehyde is converted to the parent acid (6) by nucleophilic attack of the azido-ester (9) and intramolecular cyclization of (10) followed by hydrolysis of the methyl ester (11). The cytotoxicity of the target molecules (5a-h) was evaluated in four tumour cell lines in vitro. One compound (5d) showed sufficient activity (IC50 = 10.2 ?M) in the human non-small cell lung cell line NSCLC-N16-L16 to be worthy of further study.
Heterocycles | 2002
Andrew Tsotinis; Margarita Vlachou; Lloyd R. Kelland; David E. Thurston
A new, efficient, two-step method for the synthesis of bioactive pyrroloquinolines is described. Readily available nitroquinolines, bearing the nitro moiety in the carbocyclic ring, are treated with 4-chlorophenoxyacetonitrile in the presence of potassium tert-butoxide/THF to give the analogous vicarious nucleophilic substitution products (5, 8 and 11). These, in turn, are subjected to catalytic hydrogenation to produce 1H-pyrrolo[2,3-f]quinoline (6), 3H-pyrrolo[3,2-f]quinoline (9) and 1H-pyrrolo[3,2-h]quinoline (12) in good yields and relatively short reaction times. The differential activity of two N-alkylated 1H-pyrrolo[2,3-f]quinolines (1) in cisplatin resistant cell lines compared to the corresponding parent lines suggests that these might be useful leads for developing agents for use in drug resistant diseases.
European Journal of Pharmaceutical Sciences | 2002
Margarita Vlachou; Andrew Tsotinis; Lloyd R. Kelland; David E. Thurston
A number of pyrroloisoquinolines have been prepared by reaction of 5-nitroisoquinoline with vinylmagnesium bromide followed by N-alkylation with the appropriate 2-chloro-N,N-dialkylethylamine. Their cytotoxicity was evaluated in a number of ovarian cell lines and compared to their analogous isomeric pyrroloquinolines. Two of the new compounds, 7c and 7d, are selective toward the A2780 cisplatin-resistant line.
Letters in Drug Design & Discovery | 2005
Andrew Tsotinis; Margarita Vlachou; Andreas Eleutheriades; Peter J. Garratt; Ashley J. Ibbett; Yiu-Fai Ng; Christophe Pannecouque; Myriam Witvrouw; Erik De Clercq
A series of aromatic polycationic molecules were synthesised and tested as potential non-classical antiherpes agents. Analogue (4) had a high potency in all four of the HSV cell lines used and is far more potent than ribavirin. The fact that none of the new compounds show any selectivity for HSV-2 over HSV-1 may imply that there is no intervention of a HSV-2 glycoprotein C (gC) dependent pathway.
Journal of Medicinal Chemistry | 2006
Andrew Tsotinis; Margarita Vlachou; Demetris P. Papahatjis; Theodora Calogeropoulou; Spyros P. Nikas; Peter J. Garratt; Vincent Piccio; Stefan Vonhoff; Kathryn Davidson; Muy-Teck Teh; David Sugden
Chemistry Letters | 2001
Demetris P. Papahatjis; Spyros P. Nikas; Andrew Tsotinis; Margarita Vlachou; Alexandros Makriyannis
Chemical & Pharmaceutical Bulletin | 2002
Andrew Tsotinis; Margarita Vlachou; Andreas Eleutheriades; Effie Prinea; Darren Ebreo; David Sugden
Chemistry Letters | 2003
Andrew Tsotinis; Margarita Vlachou; Konstantinos Kiakos; John A. Hartley; David E. Thurston
Letters in Drug Design & Discovery | 2006
Andrew Tsotinis; Maria Gerasimopoulou; Margarita Vlachou; Dimitri Moreau; Christos Roussakis
Letters in Organic Chemistry | 2007
Andrew Tsotinis; Margarita Vlachou; Demetris P. Papahatjis; Spyros P. Nikas; David Sugden